Sugi Predict

Sugi Predict / Compounds / SCHEMBL6095089

SCHEMBL6095089

SCHEMBL6095089

COC(=O)c1cccc2c1CNC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 4/20 0.48
▸ LMNA P02545 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ CFTR P13569 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ CHRM3 P20309 1/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA5A P35218 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6093232 0.98 TRPA1 (0.47) TRPA1LMNATSHRALDH1A1CFTR
Hydrochloric Acid SCHEMBL29877364 0.98 TRPA1 (0.47) TRPA1LMNATSHRALDH1A1CFTR
SCHEMBL29609011 0.86 CD44 (0.49) TRPA1LMNATSHRALDH1A1CFTR
SCHEMBL29801456 0.86 PNMT (0.49) TRPA1LMNATSHR
SCHEMBL567532 0.86 PNMT (0.49) TRPA1LMNATSHR
SCHEMBL2355554 0.86 CD44 (0.49) TRPA1LMNATSHRALDH1A1CFTR
Hydrochloric Acid SCHEMBL4158562 0.84 PNMT (0.47) TRPA1LMNATSHR
Hydrochloric Acid SCHEMBL4438179 0.84 CD44 (0.47) TRPA1LMNATSHRALDH1A1CFTR
Hydrochloric Acid SCHEMBL30319882 0.84 PNMT (0.47) TRPA1LMNATSHR
SCHEMBL21496827 0.83 TSHR (0.54) TSHRALDH1A1HSD17B10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667461-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE Children's Hospital Medical Center (US) 2025-12-24 — — EP disclosed
US-20250382274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE CHILDRENS HOSPITAL MED CT (US) 2025-12-18 — — US disclosed
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2024-07-18 — — US disclosed
CN-117460507-A Compound targeting fibroblast activation protein and method of use thereof 普渡研究基金会 2024-01-26 — — CN disclosed
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS VALO HEALTH, INC. 2023-08-03 — — US disclosed
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS VALO HEALTH, INC. 2023-08-03 — — US disclosed
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS VALO HEALTH, INC. 2023-08-03 — — US disclosed
US-11535607-B2 Isoindolines as HDAC inhibitors VALO HEALTH, INC. (US) 2022-12-27 — — US disclosed
US-11535607-B2 Isoindolines as HDAC inhibitors VALO HEALTH, INC. (US) 2022-12-27 — — US disclosed
CN-110357876-B Azabicyclooctane derivative and preparation method and application thereof 浙江海正药业股份有限公司 2022-06-28 — — CN disclosed
WO-2019204550-A1 ISOINDOLINES AS HDAC INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-10-24 — — WO disclosed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 — — US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 — — US disclosed
EP-2882725-A1 SUBSTITUTED HETERO-AZEPINONES F. Hoffmann-La Roche AG (CH) 2015-06-17 — — EP disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 — — WO disclosed
WO-2008053319-A1 AMIDE RESORCINOL COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-05-08 — — WO disclosed
US-7053122-B2 Therapeutic use of aryl amino acid derivatives PFIZER INC (US) 2006-05-30 — — US disclosed
EP-1528919-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES Pfizer Limited (GB) 2005-05-11 — — EP disclosed
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives MAW GRAHAM NIGEL (GB) 2004-07-15 — — US disclosed
WO-2004014357-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES PFIZER LIMITED (GB) 2004-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 TRPA1 4839/4885LMNA 2738/4885TSHR 1000/4885
US-11535607-B2 Isoindolines as HDAC inhibitors HDAC1, HDAC2, HDAC3 TRPA1 3565/4885LMNA 1250/4885TSHR 2912/4885
US-20230242512-A1 ISOINDOLINES AS HDAC INHIBITORS HDAC1, HDAC2, HDAC3 TRPA1 3637/4885LMNA 1180/4885TSHR 3102/4885
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF FAP, FIBP, FGFR1 TRPA1 1200/4885LMNA 1909/4885TSHR 4225/4885
US-20250382274-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE GBA1, GAA, GBA2 TRPA1 4853/4885LMNA 1258/4885TSHR 4231/4885
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives CNR1, HCRTR1, HTR6 TRPA1 971/4885LMNA 632/4885TSHR 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.